Additionally, due to the low sensitivity of glypican-3 in detecting malignancy, especially in well-differentiated HCCs10, HCC should not be definitively excluded based solely on glypican-3 negativity. This evidence concerns the gene GPC3 and hepatocellular carcinoma.